Correlation Between Acrivon Therapeutics, and PennyMac Finl

Can any of the company-specific risk be diversified away by investing in both Acrivon Therapeutics, and PennyMac Finl at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Acrivon Therapeutics, and PennyMac Finl into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Acrivon Therapeutics, Common and PennyMac Finl Svcs, you can compare the effects of market volatilities on Acrivon Therapeutics, and PennyMac Finl and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Acrivon Therapeutics, with a short position of PennyMac Finl. Check out your portfolio center. Please also check ongoing floating volatility patterns of Acrivon Therapeutics, and PennyMac Finl.

Diversification Opportunities for Acrivon Therapeutics, and PennyMac Finl

-0.05

Correlation Coefficient

Acrivon Therapeutics,  PennyMac Finl

Good diversification

The 3 months correlation between Acrivon and PennyMac is -0.05. Overlapping area represents the amount of risk that can be diversified away by holding Acrivon Therapeutics, Common and PennyMac Finl Svcs in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on PennyMac Finl Svcs and Acrivon Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Acrivon Therapeutics, Common are associated (or correlated) with PennyMac Finl. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of PennyMac Finl Svcs has no effect on the direction of Acrivon Therapeutics, i.e., Acrivon Therapeutics, and PennyMac Finl go up and down completely randomly.

Pair Corralation between Acrivon Therapeutics, and PennyMac Finl

Given the investment horizon of 90 days Acrivon Therapeutics, is expected to generate 2.9 times less return on investment than PennyMac Finl. In addition to that, Acrivon Therapeutics, is 3.29 times more volatile than PennyMac Finl Svcs. It trades about 0.01 of its total potential returns per unit of risk. PennyMac Finl Svcs is currently generating about 0.06 per unit of volatility. If you would invest  6,170  in PennyMac Finl Svcs on October 4, 2024 and sell it today you would earn a total of  3,814  from holding PennyMac Finl Svcs or generate 61.82% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Acrivon Therapeutics, Common  vs.  PennyMac Finl Svcs

Acrivon Therapeutics,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Acrivon Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in February 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

PennyMac Finl Svcs

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days PennyMac Finl Svcs has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, PennyMac Finl is not utilizing all of its potentials. The newest stock price confusion, may contribute to short-horizon losses for the traders.

Pair Trading with Acrivon Therapeutics, and PennyMac Finl

The main advantage of trading using opposite Acrivon Therapeutics, and PennyMac Finl positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Acrivon Therapeutics, position performs unexpectedly, PennyMac Finl can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in PennyMac Finl will offset losses from the drop in PennyMac Finl's long position.

The idea behind Acrivon Therapeutics, Common and PennyMac Finl Svcs pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.